Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-Human CD70 T-Cell Injection in Advanced/Metastatic Renal Cell Carcinoma
NCT07647744Phase 1Recruiting
- Sponsor
- Shanghai HRAIN Biotechnology
- Start
- Jun 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-human CD70 T-cell injection in renal cell carcinoma (RCC), sponsored by Shanghai HRAIN Biotechnology. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Jun 2026; status: recruiting.
02
Drugs
anti-human CD70 T-cell injection
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07647744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07647744.